Vor Biopharma Announces Positive Phase 3 Trial Results for Telitacicept in Lupus, Published in NEJM
Reuters
Oct 16, 2025
Vor Biopharma Announces Positive Phase 3 Trial Results for Telitacicept in Lupus, Published in NEJM
Vor Biopharma Inc. has announced the publication of results from a Phase 3 clinical study evaluating telitacicept in patients with systemic lupus erythematosus $(SLE)$ in The New England Journal of Medicine. The study, conducted at 42 hospitals in China and sponsored by RemeGen Co., Ltd., included 335 patients with active SLE despite standard therapy. Telitacicept demonstrated a statistically significant improvement in disease activity, with 67.1% of patients achieving a modified SLE Responder Index-4 (SRI-4) response at week 52, compared to 32.7% in the placebo group (P<0.001). Additional secondary measures, such as SELENA-SLEDAI score reduction, also favored telitacicept. The results have already been presented through publication in a peer-reviewed journal.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546514-en) on October 16, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.